How New Analyst Coverage Spotlighting Brepocitinib’s Phase 3 Readouts At Roivant Sciences (ROIV) Has Changed Its Investment Story

In April 2026, Piper Sandler and Bernstein initiated coverage on Roivant Sciences, emphasizing the company’s inflammation and immunology pipeline, including late-stage programs such as brepocitinib across multiple immune-mediated diseases.
This fresh analyst attention places brepocitinib’s upcoming dermatomyositis, non-infectious uveitis, and cutaneous sarcoidosis readouts at the center of Roivant’s medium-term outlook.
We’ll now examine how this renewed focus on brepocitinib’s upcoming Phase 3 data could reshape Roivant Sciences’ existing investment narrative.

We’ve uncovered the 13 dividend fortresses yielding 5%+ that don’t just survive market storms, but thrive in them.

Roivant Sciences Investment Narrative Recap

The basic Roivant thesis is about turning a broad inflammation and immunology pipeline into real commercial products, with brepocitinib as a key pillar. The new coverage from Piper Sandler and Bernstein spotlights that story but does not change the core near term catalyst, which remains brepocitinib’s late stage readouts, or the main risk, which is clinical and execution setbacks across multiple ongoing trials.

Among recent announcements, the positive Phase 3 VALOR data for brepocitinib in dermatomyositis and the plan to file an NDA in H1 2026 align most directly with this renewed analyst focus. Together with the expanding Phase 2b/3 program in lichen planopilaris, they frame how much of Roivant’s near term value hinges on translating brepocitinib’s clinical profile into approvals across several immune mediated diseases.

Yet behind this enthusiasm, investors should be aware that late stage trial failures or only modest efficacy versus existing therapies could…

Read the full narrative on Roivant Sciences (it’s free!)

Roivant Sciences’ narrative projects $1.4 billion revenue and $206.2 million earnings by 2029.

Uncover how Roivant Sciences’ forecasts yield a $35.67 fair value, a 28% upside to its current price.

Exploring Other Perspectives

Before this analyst attention, the most bullish views assumed revenue could reach about US$2.5 billion and earnings US$292.3 million by 2028, so this fresh focus on brepocitinib’s readouts may either reinforce or challenge that much more optimistic path compared with the more cautious consensus story.

Explore 4 other fair value estimates on Roivant Sciences – why the stock might be worth over 2x more than the current price!

The Verdict Is Yours

Don’t just follow the ticker – dig into the data and build a conviction that’s truly your own.

A great starting point for your Roivant Sciences research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
Our free Roivant Sciences research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Roivant Sciences’ overall financial health at a glance.

Looking For Alternative Opportunities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

Capitalize on the AI infrastructure supercycle with our selection of the 38 best ‘picks and shovels’ of the AI gold rush converting record-breaking demand into massive cash flow.
Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.
The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.